4 min read

Portfolio Update: Is That "It" for Moderna?

My view remains that MRNA's selloff is actually a good thing. It takes pressure off the stock, which has become what Wall Street-types like to call a "crowded trade" as momentum traders piled on in recent months as the share price ran from $200 to nearly $500.
Portfolio Update: Is That "It" for Moderna?

This post is for paying subscribers only